Featured in P&T Community: Napabucasin’s Potential for Treating Advanced Colorectal Cancer

P&T Community, a print and online publication that reports on drug forecasts and analysis for a target audience of pharmacy and therapeutic committee members, recently published an in-depth article in the April 2017 issue exploring investigational therapies in development for the treatment of advanced colorectal cancer (CRC).

In addition to including background information on the role of cancer stemness and STAT3 expression in this disease, the article outlines phase 1b/2 results of napabucasin in combination with panitumumab in patients with advanced KRAS wild-type metastatic CRC. The article also includes study details of the ongoing CanStem303C trial with napabucasin in combination with FOLFIRI in patients with metastatic CRC. Looking ahead to the future of napabucasin, the article states, “If napabucasin is approved, it is expected to be the first cancer stem cell inhibitor in the CRC marketplace.”

Promising Drugs in Clinical Development to Treat Advanced Colorectal Cancer